BIS outlines how pharmaceutical companies can seek company-specific onshoring agreements to reduce new 100% Section 232 tariffs on patented drugs and ingredients.
| less than a minute read
BIS Issues Procedures for Onshoring Agreements to Mitigate 100% Tariffs on Patented Pharmaceuticals

/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-06-29-18-48-59-216-6a42be1b7a098eca6521ac87.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-06-29-18-47-49-003-6a42bdd57a098eca6521aa8c.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-06-29-18-46-59-635-6a42bda3ff1fff48097384d8.jpg)
/Passle/6880addbd954bf894713d5af/SearchServiceImages/2026-06-29-18-07-44-968-6a42b4707a098eca65215f2a.jpg)